Summit Therapeutics (SMMT) to Release Earnings on Monday

Summit Therapeutics (NASDAQ:SMMT) will likely be announcing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $75.4690 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 12:30 PM ET.

Summit Therapeutics Price Performance

Shares of SMMT stock opened at $14.96 on Monday. Summit Therapeutics has a 1-year low of $13.83 and a 1-year high of $36.91. The firm has a market cap of $11.54 billion, a PE ratio of -12.06 and a beta of -1.44. The company has a 50-day moving average of $16.86 and a two-hundred day moving average of $19.72.

Hedge Funds Weigh In On Summit Therapeutics

Several large investors have recently bought and sold shares of SMMT. Kestra Advisory Services LLC purchased a new stake in Summit Therapeutics during the 4th quarter worth about $28,000. Parallel Advisors LLC acquired a new stake in shares of Summit Therapeutics during the 3rd quarter worth about $39,000. Quantbot Technologies LP purchased a new stake in Summit Therapeutics during the second quarter worth approximately $132,000. California State Teachers Retirement System boosted its holdings in Summit Therapeutics by 62.3% in the second quarter. California State Teachers Retirement System now owns 7,368 shares of the company’s stock valued at $157,000 after purchasing an additional 2,828 shares in the last quarter. Finally, Amundi acquired a new position in Summit Therapeutics in the second quarter valued at approximately $258,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on SMMT. Zacks Research cut shares of Summit Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 4th. JMP Securities restated a “market outperform” rating and set a $40.00 price target on shares of Summit Therapeutics in a research report on Monday, October 20th. Wolfe Research began coverage on Summit Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Piper Sandler set a $40.00 target price on Summit Therapeutics in a research note on Wednesday, January 14th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $40.00 target price on shares of Summit Therapeutics in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $33.62.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.